Neuroscience this week

Neuroscience This Week: October 18, 2026

Each week Dr. Missios picks a handful of stories, sums them up in plain language and says what he makes of them.

Issue
This issue

October 18, 2026

Devices and brain-computer interfaces
Early human studies

Depression-relief pathways in deep brain stimulation mapped more precisely

Researchers studying patients with severe, treatment-resistant depression who received deep brain stimulation identified three specific brain pathways tied to lasting improvement. They also found that people who did not improve after two years tended to share one thing: insufficient stimulation of a particular brain connection. The implication is that the exact placement of the electrode, down to a few millimeters, may determine whether a patient responds. This adds detail to a treatment that is still used selectively and mostly in research or specialized centers for the most severe, medication-resistant cases.

Dr. Missios's take

Deep brain stimulation for depression is not something I implant myself, but I follow this field closely because so many of my patients ask about it after exhausting other options. The idea that millimeters of electrode placement separate response from no response tells you how unforgiving this surgery is, and why it belongs in centers that do it often. This is a refinement of an existing treatment, not a new one, and it is still reserved for the most severe, treatment-resistant cases.

Source: ScienceDaily Neuroscience
Ask about this
Rare and genetic disease
Proven in trials

First targeted drug approved for rare, fatal brain disease Alexander disease

Dr. Missios's take

For a disease this rare, having any targeted drug at all is real progress, and three decades of grinding research got us here. I have not treated this disease myself, but I know what it means to a family to go from no options to one option. The caveat worth saying plainly is that stabilizing or modestly improving motor function is not a cure, and we need longer follow-up to know how durable this benefit is.

The FDA has approved a new drug called Zanvastro as the first treatment that directly targets Alexander disease, a rare and severe neurological disorder that affects fewer than one in a million people. The approval follows roughly 30 years of research into the disease’s underlying biology. In clinical trials, the drug stabilized motor function in patients, and some showed improvement in movement. Alexander disease has had no disease-modifying treatment until now, so this marks a genuine shift for a small population of patients and families who previously had only supportive care to offer.

Source: ScienceDaily Neuroscience
Ask about this
Policy and access

Patient advocacy pushes UK government to announce new brain cancer measures

Dr. Missios's take

I operate on these tumors, and I can tell you that patient and family advocacy has moved the needle on funding and research attention in ways that quiet lobbying never has. What matters now is whether the announcement translates into actual trial funding and faster access to new treatments, not just headlines. Families dealing with a glioblastoma diagnosis should watch for concrete funding commitments, not just the meeting itself.

A televised appeal by swimmer Archie Goodburn, who has been affected by brain cancer, led to a meeting with the UK prime minister and a government announcement of new measures aimed at improving brain cancer care. Details of the specific policy changes were not fully spelled out in initial coverage, but the episode reflects ongoing pressure from patients and families on a disease that has seen comparatively little treatment progress over the past few decades. Brain cancer, including glioblastoma, remains one of the hardest cancers to treat, with survival rates that have improved only modestly despite decades of research investment. Advocacy campaigns like this one are part of how funding priorities and care standards shift over time.

Source: BBC Health
Ask about this
Brain tumors
Lab work

Study finds brain tumors change genetically when they come back after treatment

Dr. Missios's take

Every patient whose tumor comes back asks me the same question: why isn’t the same treatment working anymore? This kind of genetic study is starting to answer that, showing the tumor is not static, it adapts under treatment pressure. This is still research-stage work, but it points toward a future where we choose second-line treatment based on what the recurrent tumor actually looks like, not just what the first one was.

Researchers examined what happens at the genetic level when certain brain tumors recur after initial treatment, a question that has long puzzled doctors trying to manage these cases. The study found that recurrent tumors often carry distinct genetic changes not present in the original tumor, suggesting the cancer evolves in response to treatment pressure. This matters because a drug or approach that worked on the first tumor may not work on the version that returns. Understanding these changes could eventually help guide which treatments to try at relapse rather than repeating the original approach by default.

Source: News-Medical Neurosurgery
Ask about this
Other
Lab work

Experimental gene therapy tested as non-surgical option for hydrocephalus

Dr. Missios's take

I put in shunts regularly, and I also see the complications: blockages, infections, revisions, sometimes years later. A biological fix that reduces or eliminates the need for hardware in the brain would be a genuine advance, so I want this to work. But this is proof-of-concept science, not a clinical trial, and the honest answer for a family asking about it today is that shunt surgery remains the only treatment we actually have to offer.

Researchers at the University of Cincinnati published early proof-of-concept data on a gene therapy approach intended to treat hydrocephalus without the shunt surgery that is currently the standard treatment. Hydrocephalus involves a buildup of fluid in the brain and is usually managed with a surgically implanted shunt that drains excess fluid, a device that can fail or become infected over time. The new approach aims to address the underlying fluid regulation problem directly rather than mechanically diverting it. This is early-stage research, likely done in animal models or cell systems rather than patients, and a usable treatment is still years away if it pans out at all.

Source: News-Medical Neurosurgery
See it in 3DAsk about this
Head injury

Experts call for lifelong follow-up care after brain and spinal cord injuries

Dr. Missios's take

This matches what I see in practice: the acute surgery is often the easy part, and the years afterward are where patients and families struggle without enough support. A fusion or a craniotomy fixes a structural problem, but it does not fix the cognitive fog, the mood changes, or the slow physical decline that can follow a serious brain or spinal cord injury. This paper is a policy argument, not a new treatment, but it is aimed at the right problem.

An international group of specialists, writing in The Lancet Neurology, argues that traumatic brain injury and spinal cord injury should be reframed as chronic, lifelong conditions rather than one-time events treated and then considered resolved. They propose integrated, long-term care models that follow patients for years after the initial injury, addressing ongoing physical, cognitive, and psychological effects that can emerge or worsen over time. Currently, many patients are discharged from acute care with limited long-term follow-up, even though complications like seizures, mood changes, and physical decline can appear or persist for decades. The paper is a call for a systemic shift in how health systems organize care, not a new treatment or trial result.

Source: News-Medical Stroke
Ask about this
Stroke and vascular

Stroke rates rising among Black communities, BBC investigation finds

Dr. Missios's take

Time is brain in stroke care, and that saying only helps patients if they get to a stroke center fast and if the system works the same way for everyone. Disparities in access and awareness translate directly into worse outcomes, because thrombectomy and clot-busting drugs only work within a narrow window. This is a public health problem as much as a medical one, and closing the gap requires faster recognition of symptoms in every community, not a new drug.

A BBC Radio program examined why stroke rates are rising among Black communities, pointing to a combination of factors including higher rates of underlying risk conditions like hypertension, disparities in access to timely care, and gaps in public health messaging tailored to these communities. Stroke remains a leading cause of death and long-term disability, and timely treatment, within hours of symptom onset, dramatically affects outcomes. The segment highlights how social and structural factors, not just individual biology, shape who has a stroke and how well they recover. It is a public health and health-equity story rather than a new clinical finding.

Source: BBC Health
Ask about this
Dementia and aging

People with epilepsy may face higher risk of early-onset dementia

Dr. Missios's take

Patients with epilepsy already worry enough about seizures affecting their daily life, and now there is a reasonable question about long-term cognitive risk to address honestly. This is an association from large datasets, not a cause-and-effect proof, so no one should panic based on this alone. What it does support is the existing advice to get seizures as well controlled as possible, since uncontrolled seizures are bad for the brain regardless of this particular finding.

A study published in Neurology found that people with epilepsy may be more likely to develop young-onset dementia, meaning dementia diagnosed before age 65, compared with people who do not have epilepsy. The research tracked health outcomes over time, though the exact mechanism linking the two conditions is not yet clear. Possible explanations include shared underlying brain changes, effects of repeated seizures on brain tissue, or side effects of long-term anti-seizure medications. This is an observational association, not proof that epilepsy causes dementia, and more research is needed to understand the connection and whether better seizure control might reduce the risk.

Source: News-Medical Stroke
Ask about this
How close is this to patients? Lab work: tested in cells or animals, not yet in people. Early human studies: first tests in a small number of patients. Proven in trials: shown to work in larger trials, or newly approved. Standard care: already routine treatment or part of a guideline. Tags are a draft for Dr. Missios to review.

News summaries and opinion, not medical advice. Talk to your own doctor about your situation.